Chapin Davis, Inc. Abb Vie Inc. Transaction History

Chapin Davis, Inc.

$407 Billion
Q3 2025

A detailed history of Chapin Davis, Inc. transactions in Abb Vie Inc. stock. As of the latest transaction made, Chapin Davis, Inc. holds 13,468 shares of ABBV stock, worth $3.07 Million. This represents 0.77% of its overall portfolio holdings.

Number of Shares

13,468

Previous 13,006 3.55%

Holding current value

$3.07 Million

Previous $2.41 Billion 29.17%

% of portfolio

0.77%

Previous 0.67%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Oct 09, 2025	BUY	$184.85 - $231.54 $85,400 - $106,971	462 Added 3.55%	13,468 $3.12 Billion
Q2 2025 Jul 14, 2025	BUY	$170.16 - $206.27 $253,027 - $306,723	1,487 Added 12.91%	13,006 $2.41 Billion
Q1 2025 Apr 22, 2025	BUY	$169.2 - $216.66 $320,126 - $409,920	1,892 Added 19.65%	11,519 $2.41 Billion
Q3 2024 Oct 07, 2024	BUY	$163.84 - $199.33 $35,225 - $42,855	215 Added 2.28%	9,627 $1.9 Billion
Q2 2024 Jul 19, 2024	BUY	$154.79 - $180.76 $52,628 - $61,458	340 Added 3.75%	9,412 $1.61 Billion
Q1 2024 Apr 17, 2024	SELL	$159.82 - $182.1 $383,568 - $437,040	-2,400 Reduced 20.92%	9,072 $1.65 Billion
Q4 2023 Jan 11, 2024	BUY	$137.6 - $154.97 $154,800 - $174,341	1,125 Added 10.87%	11,472 $1.78 Billion
Q3 2023 Oct 19, 2023	SELL	$133.59 - $154.65 $98,723 - $114,286	-739 Reduced 6.67%	10,347 $1.54 Billion
Q2 2023 Aug 30, 2023	BUY	$132.51 - $164.9 $5,697 - $7,090	43 Added 0.39%	11,086 $1.49 Billion
Q1 2023 Apr 12, 2023	BUY	$144.61 - $166.54 $25,885 - $29,810	179 Added 1.65%	11,043 $1.76 Billion
Q4 2022 Jan 27, 2023	BUY	$138.31 - $165.87 $1.5 Million - $1.8 Million	10,864 New	10,864 $1.76 Billion

Others Institutions Holding ABBV

# of Institutions

4,372

Shares Held

1.3B

Call Options Held

16.1M

Put Options Held

10.9M

View Full List

About AbbVie Inc.

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $403B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

More about ABBV

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Chapin Davis, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Chapin Davis, Inc. with notifications on news.

Account